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Dear Editor,
Although therapy-related acute leukemia (tAL) is a well-recog-
nized clinical syndrome and is increasing owing to the prolonged 
survival of patients treated with chemoradiotherapy [1], tAL with 
mixed phenotype is extremely rare. Only four cases of tAL with 
mixed phenotype have been reported worldwide; among them, 
only one case occurred after hematologic malignancy [2, 3]. Here, 
we report a rare case of tAL with mixed phenotype with BCR-
ABL1 after achieving complete remission (CR) of diffuse large 
B-cell lymphoma (DLBCL).
A 57-yr-old woman with Hashimoto’s disease was admitted 
with chronic epigastric discomfort in August 2009. She was di-
agnosed as having non-Hodgkin lymphoma with supraclavicular 
lymph node metastasis (stage IV). There was no evidence of lym-
phoma involvement or chromosomal abnormalities on bone mar-
row examination. She received rituximab, cyclophosphamide, 
vincristine, prednisone and achieved CR. During follow-up in 
October 2012, endoscopy revealed a 4-cm round, infiltrating 
mass on the duodenal bulb. A biopsy revealed DLBCL. The pa-
tient received rituximab, cyclophosphamide, vincristine, hydroxy-
daunorubicin, prednisone with granulocyte colony-stimulating 
factor (G-CSF) injected after each cycle and achieved CR.
In August 2015, the patient was readmitted to the hospital af-
ter a follow-up examination revealed the presence of immature 
cells in the blood. Physical examination showed no specific find-
ings, and complete blood count findings were as follows: hema-
tocrit, 35.1%; hemoglobin, 116 g/L; platelet count, 129×109/L; 
and white blood cell count, 2.41×109/L, with 4% blasts, 26% 
segmented neutrophils, 3% band neutrophils, 39% lymphocytes, 
and 26% monocytes. Bone marrow aspirate smears revealed 
40.7% leukemic blasts with medium cell size, oval to round shape, 
vesicular nuclei, fine chromatin patterns, and basophilic cyto-
plasm (Fig. 1A). On cytochemical staining, blasts were negative 
for Periodic acid–Schiff and non-specific esterase staining, but 
were positive for myeloperoxidase staining (Fig. 1B). Flow cyto-
metric analysis showed that the blasts were positive for both T-
lymphoid and myeloid markers (cytoplasmic CD3, 87%; CD5, 
90%; CD7, 96%; cytoplasmic myeloperoxidase, 20%; CD13, 
91%; CD33, 87%; Fig. 2) and negative for CD2, CD10, CD11b, 
CD14, CD15, CD19, CD20, CD61, CD117, and terminal deoxy-
nucleotidyl transferase. Immunophenotyping fulfilled the diag-
nostic criteria of T/myeloid biphenotypic leukemia based on the 
scoring system of the European Group for the Immunological 
Characterization of Leukemias and WHO classifications [4, 5]. 
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Fig. 1. Bone marrow aspirate smear showing leukemic blasts. (A) Increased blasts with medium cell size, oval to round shape, vesicular 
nuclei, fine chromatin patterns, and basophilic cytoplasm (×1,000, Wright-Giemsa stain), (B) More than 3% of blasts were positive for my-
eloperoxidase (×1,000, myeloperoxidase stain).
A B
Fig. 2. Flow cytometry analysis of the bone marrow cells (Cytomics FC500 flow cytometer, Beckman Coulter, Fullerton, CA, USA). By CD45/
SS linear gating, a relatively homogenous population of blasts consist 38.46% of all bone marrow cells. These cells were positive for both T-
lymphoid (cytoplasmic CD3, CD5, and CD7) and myeloid differentiation (cytoplasmic MPO, CD13, and CD33) markers.
Abbreviations: FITC, fluorescein isothiocyanate; MPO, myeloperoxidase.  
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FISH using the locus specific identifier BCR/ABL dual-color, dual-
fusion translocation probe set (Abbott Molecular/Vysis, Des Plai-
nes, IL, USA) was negative, but multiplex reverse transcription 
PCR (mRT-PCR) using HemaVision kit (Bio-Rad Laboratories, 
Hercules, CA, USA) revealed the presence of minor BCR-ABL1 
(e1a2) fusion transcripts. False-positive results were minimized 
by using a previously diagnosed BCR-ABL1-positive patient sam-
ple as a positive control and normal patient sample as a nega-
tive control. As some reports claim that mRT-PCR is more sensi-
tive than FISH in detecting cryptic translocations or submicro-
scopic insertion that are incapable of generating signals large 
enough to be visualized [6], the result may be due to submicro-
scopic translocation. Chromosome analysis of bone marrow cells 
failed because of insufficient mitotic cells. Immunoglobulin heavy 
chain gene rearrangement and T cell receptor-γ gene rearrange-
ment were not detected on bone marrow aspirates. 
The patient was diagnosed as having tAL with T/myeloid phe-
notype and minor BCR-ABL1 according to the 2008 WHO clas-
sification. She refused chemotherapy and succumbed in Decem-
ber 2015.
Mixed phenotype acute leukemia (MPAL) is an uncommon 
subtype that comprises 0.5-1% of leukemia. The T/myeloid phe-
notype is rarer and represents 35% of all MPAL cases [7]. Phil-
adelphia chromosome is the most frequent chromosomal ab-
normality, accounting for approximately 30% of MPAL cases [8].
The risk of secondary malignancies after lymphoma treatment 
is relatively increased for leukemia. AML, ALL, MDS, CML and 
chronic myelomonocytic leukemia are reported secondary he-
matologic malignancies [1, 9]. Until now, only one case of tAL 
with mixed phenotype after lymphoma has been reported [3]. 
To the best of our knowledge, this is the second case of tAL with 
mixed phenotype after DLBCL. This case is also unique because 
the BCR-ABL1 has not been described in the literature for pa-
tients with tAL with mixed phenotype, after hematologic malig-
nancy.
According to the 2008 WHO classification, tAL can be attrib-
uted to radiation, alkylating agents, or topoisomerase II inhibi-
tors [4]. Our patient did not receive radiation therapy but previ-
ously received cyclophosphamide and doxorubicin. Furthermore, 
some investigators have suggested that G-CSF stimulates prolif-
eration of not only myeloid lineage cells but also some leukemic 
blast cells, including those of biphenotypic leukemia [10]. Thus, 
G-CSF injection might have played an additional role in this pa-
tient.
Therefore, this is the first case of tAL with mixed phenotype 
and BCR-ABL 1 after alkylating agent and topoisomerase II in-
hibitor therapy for DLBCL. 
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